NRAS and melanoma: At Vanderbilt, patient melanomas are routinely screened for well-established and targetable driver point mutations in BRAF (codon V600), NRAS (G12, G13, and Q61), KIT (W557, V559, L576, K642, and D816), GNAQ (Q209) and GNA11 (Q209) with a multiplex-PCR and capillary electrophoresis-based assay termed SNaPshot (Supplementary Table S1) [25].